Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.
about
Nonsteroidal Anti-Inflammatory Drugs and the KidneyViscosupplementation during rehabilitation.Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patientsLumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.NSAIDs Alter Phosphorylated Forms of AQP2 in the Inner Medullary Tip.Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature.Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors.Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity.Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies.Renal adverse effects of nonsteroidal anti-inflammatory drugs.Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment.Gout and organ transplantation.Gout and its comorbidities: implications for therapy.Optimizing current treatment of gout.The prevention of contrast-induced nephropathy.Dental implant treatment for renal failure patients on dialysis: a clinical guideline.Importance of early electrocardiographic recognition and timely management of hyperkalemia in geriatric patientsAcute Kidney Injury Secondary to NSAID Diagnosed on 99mTc MDP Bone Scan.Urinary protein profiles in ketorolac-associated acute kidney injury in patients undergoing orthopedic day surgery.Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses.Emerging importance of residual renal function in end-stage renal failure.Morphine induces mesangial cell proliferation and glomerulopathy via kappa-opioid receptors.Lithium intoxication as a result of an interaction with rofecoxib.Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.The effect of parecoxib on kidney function at laparoscopic hysterectomy.Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.Renal effect of meloxicam versus ketoprofen in anaesthetized pseudo-normovolaemic piglets.Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats.Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided.Effect of short-term treatment with meloxicam and pimobendan on the renal function in healthy beagle dogs.Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.Ketogal: A Derivative Ketorolac Molecule with Minor Ulcerogenic and Renal Toxicity.Leukotrienes and kidney diseases.Clinical Efficacy and Safety of Benjakul Remedy Extract for Treating Primary Osteoarthritis of Knee Compared with Diclofenac: Double Blind, Randomized Controlled Trial.A survey of dog and cat anaesthesia in a sample of veterinary practices in New Zealand.
P2860
Q28386844-E65117DD-237E-4854-9E71-B78AB8FB7B94Q34064751-3BEFC368-2E2F-42F4-845F-20910174D8E3Q34325249-DCBA02CC-6634-427A-9B81-BB04499E6393Q34326687-51416889-CF78-44BE-91D1-5A94176CCED4Q34449825-5D198239-4057-42BC-9BB8-353E0E3BE618Q34571335-DDFB913A-B734-480C-A501-322C84D531E9Q35827119-EDF705D4-94CD-45AE-9489-61656519724CQ35873398-2042F499-3885-45BF-8A12-C30218CF9C79Q35976831-479C0A1F-E50E-4AFD-894D-D4BA8C6000EBQ36544954-428A2187-11ED-496D-96E5-54F2180EA9C7Q37397801-13FC4D69-F76B-47FC-A807-A8FC93D38933Q37448363-EFA3837C-B93A-44AE-BE9A-D30CC1B28331Q37615395-CB16FA11-EEDD-4FF6-A9B6-4CE384820629Q37772732-9BA49A33-3F69-4370-961C-45E87A1E229EQ37976996-0BBD64AE-154E-46D9-905B-E097F37D8AD4Q38040777-3F584EC2-989D-4BDD-8095-509161F490C8Q38194896-347C2C54-54B8-4944-9608-9423C50FA230Q38226255-BFCF9C8D-FF7F-4063-8BB1-800B0C70220FQ39394204-5AD49287-2360-4413-93B6-6C1CACAC7C6AQ41836593-FFF38C5F-40F5-4958-9FB9-CC8A890D008AQ42148083-29EDF70B-00F7-445C-8562-86A178D9DA62Q42731706-EAA15E9C-230C-4650-8E6E-FF5EDB22616CQ43655467-0AFA7D15-3F08-41BC-BD38-DCA1FD268B2CQ44232525-6529313D-D3B8-4414-8131-BC9673222A37Q44338350-A5A7D990-8A5E-4633-8D7B-3F89660944D5Q44929052-55546187-FCF9-407B-BF57-059530F37286Q45276638-A78B1C26-69FD-4186-B35A-254386275C8BQ46001024-A8A6A06B-90C7-4924-801A-3C15E687A1C8Q46043878-2D45381C-0AF7-41A7-9E31-F56F2C352271Q46083837-62E3F367-B62E-40D2-9919-CEAA503CE5E4Q46319113-4C559FD3-8405-4E1E-8638-36F1004EC062Q46565086-2C101866-2A8C-4AC8-BA69-103491C1B177Q46728015-CDE346F6-ED17-4615-8E4D-69945E7C5A91Q46846908-931B2B73-25B6-45EA-BC05-EC1703531EE1Q47143757-25D6F659-C43B-47B7-9474-0536A5424CF5Q47153085-1236B5E0-D73A-43E5-AA02-2A79B995BE91Q47173254-58D544E4-4F39-403F-B2DC-E965F33197CDQ47224224-F6473170-048B-4EE6-9ADB-CDE959FA1F0F
P2860
Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@ast
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@en
type
label
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@ast
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@en
prefLabel
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@ast
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@en
P1476
Adverse renal effects of anti- ...... ive cyclooxygenase inhibitors.
@en
P2093
Perazella MA
P304
P356
10.1046/J.1365-2796.2003.01146.X
P407
P577
2003-06-01T00:00:00Z